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Abstract
Background. Patients with IgA nephropathy (IgAN) have
an increased amount of abnormally O-glycosylated IgA1
in circulation, in glomerular deposits and produced by tis-
sue cells in vitro. Although increased production of Th2
cytokines by peripheral blood lymphocytes and a function-
al abnormality of core 1 β1,3-galactosyltransferase
(C1β3Gal-T) have been proposed as mechanisms under-
lying pathogenesis of IgAN, they are still obscure and
are not connected.
Methods. To clarify the effect of T-cell cytokines, we ana-
lysed the mRNA levels of C1β3Gal-T and its molecular
chaperone Cosmc, C1β3Gal-T activity and subsequent
O-glycosylation of IgA1 in a human B-cell line stimulated
with these cytokines. The surface IgA1-positive human
B-cell line was cultured with recombinant human IFN-γ,
IL-2, IL-4 or IL-5. The production and glycosylation of
IgA1 were determined by sandwich ELISA and enzyme-
linked lectin binding assay, respectively. The mRNA levels
of C1β3Gal-Tand Cosmc were quantitatively measured by
real-time PCR. C1β3Gal-T activity was analysed using
high-performance liquid chromatography.
Results. IgA1 production by IL-4-stimulated cells was sig-
nificantly higher than controls or after IFN-γ or IL-5. The
terminal glycosylation of secreted IgA1 was altered in re-
sponse to IL-4. IL-4 stimulation significantly decreased
the mRNA levels of both C1β3Gal-T and Cosmc and of
C1β3Gal-T activity. IL-4 stimulation was clearly blocked
by recombinant human IL-4 soluble receptor.
Conclusions. It appears that Th2 cytokine IL-4 may play
a key role in controlling glycosylation of the IgA1 hinge
region.
Keywords: IgA1 hinge region; T-cell cytokines; the surface IgA1-positive
human B-cell line; Th2 response
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IgA nephropathy (IgAN) is the commonest form of glom-
erulonephritis in the world, and a significant proportion of
patients progress to end-stage renal disease [1–5]. Human
serum IgA consists of two subclasses, IgA1 and IgA2,
structurally and functionally distinct. The diagnostic hall-
mark of the condition in IgAN is selective deposition of
the IgA1 subclass, at least partly polymeric, in the glom-
erular mesangium. This subclass bias may arise from the
higher ratio of IgA1 (85%) to IgA2 (15%) in serum [1–6].
IgA1 differs from IgA2, particularly at the hinge region;
IgA1 contains an extended polyproline peptide bearing
multiple serine and threonine residues and distinctive
O-glycans. Core 1, Galβ1,3GalNAcα-serine/threonine, is
the major constituent of the O-glycan structures normally
present in the IgA1 hinge region. Recently, it was reported
that O-linked Galβ1,3GalNAc content is significantly de-
creased in IgA1 purified from serum, glomerular mesan-
gial deposits and tonsils of patients with IgAN compared
tocontrols[6–11].Therefore,theabnormalO-glycosylation
of IgA1 in IgAN has been extensively investigated in recent
years,andthereisincreasingevidenceforitsinvolvementin
the pathogenesis of IgAN [12–18].
Core 1 β1,3-galactosyltransferase (C1β3Gal-T) trans-
fers galactose (Gal) from UDP-Gal to an N-acetylgalacto-
samine (GalNAc) residue on glycoproteins, including
IgA1 via a β1,3-linkage [19,20]. Although a functional ab-
normality of C1β3Gal-T has been proposed as a mechan-
ism for altered O-glycosylation in IgAN, there is a paucity
of information on the regulation of expression of this gly-
cosyltransferase [6,21] or its molecular chaperone Cosmc,
which is involved in the folding or stability of C1β3Gal-T
[22]. Without Cosmc, translated C1β3Gal-T is lost, and
there is deficiency of Gal residues on glycoprotein accep-
tors [22]. Mechanisms whereby C1β3Gal-T and/or Cosmc
expression might be downregulated in B lymphocytes
from IgAN patients remain unknown [23]. Although it is
not known whether altered O-glycosylation of IgA1 is
attributable to inherited defects or not, previous reports
suggested that some stimuli, in a permissive genetic back-
ground, might cause low expression of the Cosmc gene
and result in reduced C1β3Gal-T activity and subsequent
aberrant glycosylation of IgA1 in IgAN [24–29].
IgAN is a glomerular disease that is likely Th2
dependent and is observed more commonly in developed
nations [30]. An alteration in the balance of Th1 and Th2
T-cell subsets has been implicated as a mechanism to ex-
plain the pathogenesis of IgAN. Although it was reported
that increased production of Th2 cytokines might result
in the production of abnormally glycosylated IgA in
mice, murine IgA has only N-glycosylated residues and
lacks O-linked oligosaccharides [31–33]. Moreover, no
investigation has attempted the analysis of IgA1 glycosy-
lation using human B cells stimulated with T-cell cyto-
kines. Interestingly, it was reported that O-glycosylation
of IgA1 and IgD was differentially controlled during B-
cell maturation by analysis of their lectin binding in pa-
tients with IgAN [25]. Compared with healthy controls,
O-glycosylation in IgAN was incomplete in IgA1 but
more complete in IgD. O-glycosylation of IgA1 in IgAN
might be due to aberrant immunoregulation, whereas re-
cent studies suggested that abnormal IgA1 glycosylation
is an inherited rather than an acquired trait [28,29].
Therefore, in the present study, we focused on selective
effects of T-cell cytokine stimulation upon C1β3Gal-T ac-
tivity and subsequent glycosylation of IgA1 using IgA1-
positive human B-cell line.
Materials and methods
Cell cultures and experimental protocols
ThesurfaceIgA1-positivehumanBlymphomacellline,DAKIKI,waspur-
chased from ATCC (Manassas, VA, USA) [34–36]. Cells were cultured in
75-cm
2flasksinRPMI1640mediumcontaining10%heat-inactivatedfetal
calf serum (FCS), 1 mM sodium pyruvate, 2 mM glutamine, 100 U/mL
penicillin and 100 mg/mL streptomycin and studied at passages 7–12
in RPMI 1640 medium containing 1% FCS at 37°C in a humidified at-
mosphere containing 5% CO2. To assess the effect of cytokine stimulation
on cell proliferation and the production of IgA1, cells were cultured with
10ng/mLofrecombinanthumanIFN-γ,IL-2,IL-4orIL-5(R&DSystems,
Minneapolis, MN, USA) at a density of 3 × 10
4/mL per well in 24-well
culture plates for 5 days. For analysis of IgA glycosylation, cells were
cultured with 10 ng/mL of each recombinant cytokine at a density of
3×1 0
4/mL in 100 mm culture dish for 6 days. Similarly, to assess the
effect of cytokine stimulation on mRNA expression of C1β3Gal-T and
Cosmc, cells were cultured in 6-well culture plates at a density of 1 ×
10
5/mL, with or without added IFN-γ or IL-4 (10 ng/mL) for 12, 24 or
48 h. Recombinant human IL-4 soluble receptor (IL-4sR) (R&D Systems)
(500 ng/mL) was added to parallel wells to assess the effect of IL-4. To
measure C1β3Gal-T activity, cells were cultured in 225-cm
2 flasks at a
density of 3 × 10
5/mL with 10 ng/mL of IL-4 for 24 and 72 h. After in-
cubation, the supernatants and cells were harvested for various assays. For
analysis of IgA glycosylation, the supernatants were concentrated (Ami-
con
® Ultra-4 50K, Millipore, Billerica, MA, USA). Cell viabilities, as as-
sessed by trypan blue dye exclusion, were greater than 90% in all
experiments. In each of more than two experiments, triplicate culture wells
for each stimulation were established.
Measurement of IgA1 content
IgA1 content in the supernatant from each culture well was measured
in duplicate using enzyme-linked immunosorbent assay (ELISA). All in-
cubations were performed at room temperature except for capture anti-
body coating. Briefly, 96-well immunoplates (Thermo Fisher Scientific,
Waltham, MA, USA) were coated with 5 µg/mL of F(ab′)2 fragment goat
anti-human IgA antibody (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA), in phosphate-buffered saline (PBS) at 4°C overnight.
After three washes with PBS containing 0.05% Tween-20 (PBST), plates
were blocked by adding PBS containing 1% bovine serum albumin (BSA)
to the wells for 90 min. Next, 50 µL of supernatant sample or standard
human IgA1 (CALBIOCHEM, La Jolla, CA, USA) was added to the reac-
tion wells and then incubated for 90 min. After three washes, 0.75 µg/mL
alkaline phosphatase conjugated goat anti-human IgA (Southern Biotech-
nology Associates, Birmingham, AL, USA) in 1% BSA/PBS was added to
the reaction wells and then incubated for 90 min. Plates were washed three
times and developed with a substrate solution of 1 mg/mL p-nitrophenyl
phosphate disodium salt (SIGMA, St. Louis, MO, USA) in 0.1 M glycine
buffer containing1 mM MgCl2, 1 mM ZnCl2, pH 10.4. The optical density
at 405 nm was determined in a microplate reader (Benchmark Plus
TM Bio-
Rad Laboratories, Hercules, CA, USA). IgA1 concentration in unknown
duplicatesampleswas determined byinterpolationofthe respectiveoptical
density into the appropriate standard curve. IgG and IgM contents in the
supernatant were measured using sandwich ELISA (IMMUNOtek
®, Zep-
toMetrix Corporation, Buffalo, NY, USA) according to the manufacturer’s
instructions.
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The O-glycosylation profile of IgA1 samples was measured by binding of
the lectin, Helix aspersa (SIGMA), which is specific for terminal GalNAc
[37]. Briefly, 2.5 µg/mL of F(ab′)2 fragment goat anti-human IgA anti-
body, which was the same antibody for IgA1 measurement, was utilized
for this assay to capture IgA1. Plates were washed three times and blocked
by adding 1% BSA/PBST to the wells for 3 h. The supernatants of each
culture were diluted to a final concentration of 1 µg/mL IgA1 in 1% BSA/
PBST, and 50 µL of each sample was added to the reaction wells and then
incubated at 4°C overnight. The captured IgA1 was subsequently desia-
lylated by treatment for 3 h at 37°C with 20 mU/mL neuraminidase from
Vibrio cholerae (Roche, Penzberg, Germany) in 10 mM sodium acetate
buffer, pH 5. After seven washes, 2 µg/mL of biotinylated H. aspersa
lectin diluted in 1% BSA/PBSTwas added to the reaction wells, and they
were then incubated for 3 h at 37°C. Plates were washed five times, and
lectin binding was detected with avidin-horseradish peroxidase conjugate
(ExtrAvidin
®,SIGMA) diluted in 1% BSA/PBST, and the reaction was
developed with the peroxidase chromogenic substrate o-phenylenedi-
amine-H2O2 (SIGMA). The colour reaction was stopped with 2 N
H2SO4, and the optical density in duplicate samples at 490 nm was de-
termined in a microplate reader.
RNA extraction and real-time PCR
Total RNA was extracted from each culture sample using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instruc-
tions. Synthesis of cDNA by Moloney Murine Leukemia Virus (M-MLV)
reverse transcriptase (Invitrogen) employed 1 µg RNA as a template and
random primers. Resulting cDNA (1 µg) was amplified in real time, with
a 25 µL reaction mixture containing SYBR Green PCR Master Mix (Ap-
plied Biosystems, Foster City, CA, USA), appropriate primer pairs and
water in an ABI Prism 7500 Sequence Detection system (Applied Biosys-
tems, Foster City, CA, USA). The samples were incubated at 95°C for
10 min to activate the Amplitaq Gold polymerase, followed by 40 cycles
with15sdenaturationat95°C,60sannealingat60°Cand60sextensionat
60°C. Quantification of specific mRNA in the samples was measured rela-
tive to the corresponding gene-specific standard curve. Real-time PCR re-
actionswere carried out with 5-fold serial dilutions of cDNA as a template.
The primer sets of C1β3Gal-T, Cosmc and human β-actin employed are in
Table 1. An inverse linear correlation of the Ct value with the amount of
template ensured reliable analysis of the mRNA level. The Ct values ob-
tained were used to calculate the initial quantity of each specific cDNA
by extrapolating from the standard curve derived for each primer set. All
the samplesweretestedintriplicatewiththe referencegenehumanβ-actin,
used as a housekeeping gene to normalize data.
Analysis of C1β3Gal-T activity
Cells were harvested in 1 mL of ice-cold sample buffer containing 0.25 M
sucrose, 10 mM Tris–HCl (pH 7.4), and a protease inhibitor cocktail
(#P-8340; SIGMA). Suspensions containing 5 × 10
7 cells were sonicated
three times for 10 s in an ice bath. The cell homogenates were centrifuged
at 3,900 rpm for 10 min to remove cell debris, and the supernatants were
centrifuged at 41,000 rpm for 1 h. Microsome fractions thus obtained in
the pellet were resuspended in the sample buffer containing 0.25 M su-
crose, 10 mM Tris–HCl (pH 7.4). All procedures were carried out at 4°C
[38]. The protein concentration in each sample was determined by dye
binding (BCA protein Assay Kit; PIERCE, Rockford, IL, USA) according
to the manufacturer’s instructions. A commercially available compound,
Galβ1,3GalNAcα-pNp (CALBIOCHEM), was used as a standard to es-
timate the β1,3-linkage structure. Cell homogenates were incubated in a
75-µL reaction mixture containing 0.25 mM GalNAcα-pNp (Tronto Re-
search Chemicals, North York, Ontario, Canada), 50 mM MES buffer
(pH 6.5), 20 mM MgCl2, 2 mM ATP, and 1 mM UDP-Gal (SIGMA) at
37°C for 2 h. After centrifugation (at 10,000 rpm for 10 min), the super-
natants from the samples were subjected to high-performance liquid chro-
matography (HPLC) on an OSD-80Ts QA column (4.6 × 250 mm, Tosoh,
Tokyo, Japan). The reaction products were eluted with 12% acetonitrile in
water containing 0.1% trifluoroacetic acid at a flow rate of 1.0 mL/min at
40°C and monitored with an ultraviolet spectrophotometer (absorbance at
300 nm) in a Gilson dual-pump high-pressure mixing system with detect-
or (Gilson Medical Electronics, Middleton, WI, USA). A unit of activity
defined as the area under the curve was normalized by the protein con-
centration in each sample. Each HPLC peak was isolated and subjected to
electrospray ionization-mass spectrometry (TSQ-Quantum, Thermo Elec-
tron Corporation, San Jose, CA, USA).
Statistical analysis
Values are shown as mean ± standard error (SE). Comparisons among
groups and two groups were evaluated by ANOVA and Mann–Whitney’s
U-test, respectively. Values of P < 0.05 were regarded as significant.
Results
Cell proliferation
Incubation of DAKIKI cells in the presence of IL-5 (1.5-
fold) or especially IL-4 (2.0-fold) evoked significant cell
proliferation compared to cells maintained in medium
(control) or in the presence of IFN-γ or IL-2 (P < 0.05)
(Figure 1). There was a significant difference between
the effect of IL-4 and that of IL-5 (P < 0.05).
IgA1 production
The concentration of IgA1 in supernatants from cells cul-
tured with IL-4 was 28% higher than control cells in
medium alone (P < 0.005) or cells cultured with IFN-γ
or IL-5 (P < 0.005) (Figure 2A). Addition of IL-2 to the
culture resulted in intermediate levels of IgA1 between
medium control and IL-4 stimulation. However, on a per
cell basis, IL-2 stimulation significantly increased IgA1
production by each cell (P < 0.005) (Figure 2B). Neither
IFN-γ nor IL-5 altered the production of DAKIKI cells in
culture, despite the capacity of IL-5 to increase cell num-
ber. IgG and IgM were not detected in the supernatant
from the cell culture.
Table 1. Sequences of primers used for real-time RT-PCR
Gene Primer sequence Fragment size (bp)
C1β3Gal-T 5′-AAG GTT GAC ACC CAG CCT AA-3′ (forward primer) 226
5′-CTT TGA CGT GTT TGG CCT TT-3′ (reverse primer)
Cosmc 5′-GCT CCT TTT TGA AGG GTG TG-3′(forward primer) 242
5′-TAC TGC AGC CCA AAG ACT CA-3′ (reverse primer)
human β-actin 5′-TCA CCC ACA CTG TGC CCA TCA TCG A-3′ (forward primer) 295
5′-CAG CGG AAC CGC TCA TTG CCA ATG G -3′ (reverse primer)
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Specific lectin (H. aspersa) binding to IgA1 derived from
cellsstimulatedbyIL-4wassignificantly(19%)higher than
thatfromcellsstimulatedbytheothercytokinesorunstimu-
lated cells (P < 0.005) (Figure 3). Because GalNAc occurs
onlyinoligosaccharidesofthehingeregionofIgA1,theen-
hanced binding of the GalNAc-specific lectin H. aspersa is
due to a deficiency of Gal in the O-linked side chains of the
hinge regionofIgA1.Nosignificant increaseinlectinbind-
ing was observed for IgA stimulated with the other cyto-
kines relative to the unstimulated cultures, suggesting that
no alteration of IgA1 glycosylation occurred. In summary,
only IL-4 stimulation diminished the terminal Gal on IgA1.
mRNA expression of C1β3Gal-T and Cosmc
The levels of mRNA encoding C1β3Gal-T and Cosmc in
cells coincubated with IL-4 was significantly less than
that in control after 12–48 h (P < 0.05) (Figure 4A
and B). C1β3Gal-T/Cosmc ratio of mRNA expression
stimulated by IL-4 at 12 h was higher than that at 24
or 48 h (Figure 4C). The level of C1β3Gal-T was de-
creased by 17–47% at each incubation time relative to
control cells, whereas the level of Cosmc mRNA was re-
duced more powerfully (43–6 2 % )a f t e r1 2o r2 4hb y
stimulation of IL-4 (Figure 4A and B). Addition of
IFN-γ had no significant effect on either C1β3Gal-T or
Cosmc mRNA level. The effect of IL-4 on mRNA ex-
pression of C1β3Gal-T and Cosmc was significantly pre-
vented by using IL-4sR at 24 h, 31% and 23%,
respectively, and no significant difference was found in
the results from the cells incubated with IL-4sR or un-
stimulated control.
C1β3Gal-T activity
The retention time of the standard Galβ1,3GalNAcα-pNp
(core 1-pNp) in HPLC system was 14.46 min (Figure 5A).
Each reaction product was confirmed to be core 1-pNp by
mass spectrometry (data not shown). Homogenate from
cells incubated with IL-4 contained significantly less
C1β3Gal-T activity compared to that of control cells at
each incubation time (P < 0.05) (Figure 5B). Specifically,
the enzymatic activity of C1β3Gal-T, relative to control,
wasdecreasedby22%and30%at24and72h,respectively.
C1β3Gal-Tactivityinthepresenceof10mMUDP-Galwas
not different from that in the presence of 1 mM UDP-Gal,
indicatingthatthe1mMlevelisatsubstrateexcess(datanot
shown). No significant difference of C1β3Gal-T activity
was observed between incubation times. Net enzymatic
activity on endogenous human IgA1 is measured with
thelectinbindingassayinFigure3,andthepointofFigure5
is to measure enzymatic activity objectively and quantita-
tively with a standard substrate. Comparison of Figure 3
with Figure 5 allows some evaluation as to the validity
of the synthetic substrate representing IgA1 with a similar
effect.
Discussion
Lymphocyte functions, including cytokine profiles, have
been investigated extensively in IgAN patients, and several
Fig. 2. IgA1 production in response to cytokine stimulation. IgA1
concentration of supernatant was determined by sandwich ELISA. (A)
IgA concentration of supernatant from cytokine stimulated cells. IgA1
content of supernatant from IL-4 stimulated cells was significantly
higher than that of cells incubated with other cytokines, except for IL-
2, and control (P < 0.005). (B) IgA1 production per cell stimulated by
cytokine. Production of IgA1 from each cell stimulated by IL-2 was
significantly higher than that of other cytokines or control (P < 0.005).
Results are expressed as mean ± SE.
Fig. 1. Cell proliferation in response to cytokine stimulation. After
incubation with IL-4 or IL-5, significantly more viable DAKIKI cells
were recovered compared to cells incubated with either IFN-γ and IL-2
or to control cells in medium alone (P < 0.05). There was significant
difference between IL-4 and IL-5 stimulation (P < 0.05). Neither IFN-γ
nor IL-2 significantly affected cell proliferation compared to medium
alone. Results are expressed as mean ± SE.
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T-cell cytokines known to be synthesized excessively in
IgAN are closely related not only to immunoglobulin
class switching and production but also to renal insuffi-
ciency [40–43]. Furthermore, it has been suggested that
IgAN is a glomerular disease that is likely Th2 dependent
[30].
Our results demonstrate that IL-4, one of the Th2 cyto-
kines, alters the terminal glycosylation of IgA1. As antici-
pated, IL-4 stimulation significantly induced cell
proliferation accompanied by increased IgA1 production
in vitro [44,45]. The new findings here indicate that IL-4
also downregulates mRNA expression of both C1β3Gal-
T and Cosmc and C1β3Gal-T enzymatic activity. Specific
lectin binding revealed a significant deficiency of Gal in
the O-glycans of IgA1 hinge region after IL-4 stimula-
tion. This deficiency is the one implicated as a pathogenet-
ic factor in IgAN [6–18]. No significant alteration of IgA1
glycosylation was observed by cytokine stimulation except
for IL-4.
IL-4 regulates IgE and IgA synthesis, and increased pro-
duction of IL-2 augments the IgA immune response in pa-
tients with IgAN [44,45]. Compared to healthy controls,
blood mononuclear cells from patients with IgAN produce
more IL-4 upon mitogen stimulation and express higher
levels of mRNA encoding IL-4 and IL-5 [41,42]. More-
over, IgAN patients with severe renal dysfunction are more
likely to hyperproduce Th2 cytokine and synthesize more
IL-4 compared to patients with mild disease, although they
have normal IL-4 responses during remission [41–43]. In
an experimental model of IgAN induced by Sendai virus,
Th2 predominant BALB/c mice developed more severe
nephritis with acute renal insufficiency compared to the
Th1 biased C3HeB strain of mice, which rarely developed
renal insufficiency [32]. IL-4 is recognized for its many
effects on lymphocytes and other leukocytes, but this is
the first report implicating a role for IL-4 in the regulation
of post-translational modifications of glycosylation in hu-
man B cell. IL-2 increased IgA1 secretion by each cell but
had little or no effect on cell proliferation or terminal gly-
cosylation. In contrast to IL-2, IL-5 induced significant
cell proliferation but had little or no effect on IgA1 secre-
Fig. 4. C1β3Gal-Tand Cosmc mRNA expression in response to cytokine
stimulation. The level of mRNA encoding either C1β3Gal-T (A)o r
Cosmc (B) after addition of IL-4 was significantly less than that of
control cells at each incubation time (P < 0.05 and P < 0.005,
respectively). No significant difference was found between IFN-γ and
control cultures at any incubation time. C1β3Gal-T/Cosmc ratio of
mRNA expression with IL-4 stimulation was higher at 12 h than that of
other incubation time (C). The effect of IL-4 on Cosmc mRNA levels was
significantly greater than that on C1β3Gal-T at 12 and 24 h (P < 0.05).
The efficiencies and the correlation index that were calculated from the
slopes of the standard curves of C1β3Gal-T, Cosmc and β-actin were
0.984931–1.130224 and 0.98917–0.991649, respectively. Results are
expressed as a relative ratio to control (A and B) or a ratio of C1β3Gal-T/
Cosmc (C) of each incubation time, and mean ± SE.
Fig. 3. Lectin binding to IgA1 derived from DAKIKI cells. Glycosylation
of IgA1 was assessed by enzyme-linked lectin binding assay. Lectin
binding to GalNAc of IgA1 was significantly higher after IL-4
stimulation than after stimulation by either other cytokines or medium
control (P < 0.005). None of the other cytokines significantly increased
binding of lectin relative to medium control. Results are expressed as
mean ± SE.
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synthesis itself and increased cell proliferation are not crit-
ical determinants of glycosyltransferase activity.
Core 1, the major constituent of O-glycans in IgA1 mo-
lecules, is synthesized by C1β3Gal-T [19]. Recently, the
genes encoding C1β3Gal-T and its molecular chaperone
Cosmc have been cloned [19,22]. The C1β3Gal-T gene
lies on chromosome 7p14–p13, with a 1794-bp cDNA se-
quence encoding a protein of 363 amino acids [19], the
Cosmc gene is on chromosome Xq23, with a 1471-bp
cDNA sequence encoding a protein of 318 amino acids
[22]. Cosmc is involved in the folding or stability of
C1β3Gal-T [22]. A functional abnormality of the
C1β3Gal-T responsible for the O-glycosylation of IgA1
has been proposed as a mechanism for altered O-glycosy-
lation in IgAN [19,21]. Recently, it was reported that a mu-
tation in Cosmc causes a loss of C1β3Gal-T activity
[22,38]. Therefore, the aberrant IgA1 O-glycosylation in
IgAN patients might be a consequence of reduced Cosmc
expression in B lymphocytes of patients [23]. Although we
have not yet clarified which molecule is more essential to
C1β3Gal-T activity, mRNA expression of both C1β3Gal-
T and Cosmc was reduced by IL-4 treatment in vitro col-
laterally with reduced C1β3Gal-T activity and subsequent
glycosylation of IgA1.
Previous reports suggested that aberrantly glycosylated
IgA1 molecules have an increased tendency both to self-
aggregate and to form antigen–antibody complexes with
IgG antibodies directed against IgA1 hinge epitope, fa-
vouring the generation of macromolecular aggregates of
pIgA1 and IgA immune complexes [12,13,46]. Aberrantly,
O-glycosylated IgA1 also has increased affinity for extra-
cellular matrix components such as type IV collagen, fi-
bronectin and laminin [15]. Therefore, the removal of
sialic acid and Gal residues in IgA1 can promote mesan-
gial deposition in IgAN by several mechanisms, likely
synergistic [15]. In contrast to IgA1, IgD from patients
with IgAN was more heavily O-galactosylated but less sia-
lylated than IgA1, suggesting that the pattern of immuno-
globulin O-glycosylation is differentially controlled at
different stages of B-cell development [25]. Overall, al-
tered regulation of glycosyltransferases at a particular
stage of B-cell differentiation in patients with IgAN may
have pathogenic significance for IgAN.
In summary, these findings suggest that aberrant immu-
noregulation manifest as enhanced IL-4 production in
IgAN patients might contribute to the altered O-glycosyla-
tion of the IgA1 hinge region by down-regulation of
C1β3Gal-T activity, regulated by not only C1β3Gal-T
but also its molecular chaperone Cosmc. We have little in-
formation of relevance between increased IL-4 and altered
IgA1 glycosylation in diseases other than IgAN. Although
increased IL-4 might alter IgA1 glycosylation in other in-
flammatory diseases, several other factors also could be
involved in the pathogenesis of IgAN. Further investiga-
tion is required to clarify the mechanisms whereby IL-4
downregulates both C1β3Gal-T and Cosmc mRNA levels
and whether defects in Cosmc expression and/or in the dir-
ect expression of the C1β3Gal-T are involved in the de-
fective IgA1 glycosylation in patients with IgAN.
Resolution of these issues might provide a basis for devel-
oping better methods for treating IgAN.
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Abstract
Background. Diabetic nephropathy is the leading cause
of end-stage kidney failure worldwide. It is characterized
by excessive extracellular matrix accumulation. Trans-
forming growth factor beta 1 (TGF-β1) is a fibrogenic
cytokine playing a major role in the healing process
and scarring by regulating extracellular matrix turnover,
cell proliferation and epithelial mesanchymal transdiffer-
entiation. Newly synthesized TGF-β is released as a la-
tent, biologically inactive complex. The cross-linking of
the large latent TGF-β to the extracellular matrix by
transglutaminase 2 (TG2) is one of the key mechanisms
of recruitment and activation of this cytokine. TG2 is an
enzyme catalyzing an acyl transfer reaction leading to the
formation of a stable ε(γ-glutamyl)-lysine cross-link be-
tween peptides.
Methods. To investigate if changes in TG activity can
modulate TGF-β1 activation, we used the mink lung cell
bioassay to assess TGF-β activity in the streptozotocin
model of diabetic nephropathy treated with TG inhibitor
NTU281 and in TG2 overexpressing opossum kidney
(OK) proximal tubular epithelial cells.
Results. Application of the site-directed TG inhibitor
NTU281 caused a 25% reduction in kidney levels of ac-
tive TGF-β1. Specific upregulation of TG2 in OK prox-
imal tubular epithelial cells increased latent TGF-β
recruitment and activation by 20.7% and 19.7%, respect-
ively, in co-cultures with latent TGF-β binding protein
producing fibroblasts.
Conclusions. Regulation of TG2 directly influences the
level of active TGF-β1, and thus, TG inhibition may exert
a renoprotective effect by targeting not only a direct extra-
cellular matrix deposition but also TGF-β1 activation and
recruitment.
Keywords: diabetic nephropathy; extracellular matrix; fibrosis;
transforming growth factor-β; transglutaminase
Introduction
Transforming growth factor beta 1 (TGF-β1) is a fibro-
genic cytokine that strongly stimulates the expression of
various matrix proteins [1]. While it decreases the proteo-
lytic activity of cells by modulating the expression and se-
cretion of a number of proteases and their regulators
including MMPs, TIMPs, plasmin, plasminogen activators
and plasminogen activator inhibitor-1 (PAI-1) [2], it also
modulates the expression of integrins on the cell’s surface
in a manner that facilitates attachment to the newly synthe-
sized matrix [3,4]. Furthermore, TGF-β is able to induce
myofibroblast transformation [5] that is associated with tu-
bulointerstitial fibrosis [6]. Most importantly, it can auto-
induce its own production and subsequently amplifies the
above actions [7]. Therefore, it is considered the main
regulator of the scarring process.
Newly synthesized TGF-β is secreted as a latent, bio-
logically inactive peptide containing the N-terminal se-
quence latency-associated peptide (LAP). For efficient
secretionandcorrectfoldingofTGF-β ,apartner molecule,
latentTGF-β-bindingprotein(LTBP),isrequired[8].When
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